Report cover image

Global Human Immunodeficiency Virus (HIV) Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 198 Pages
SKU # APRC20361954

Description

Summary

According to APO Research, The global Human Immunodeficiency Virus (HIV) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Immunodeficiency Virus (HIV) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human Immunodeficiency Virus (HIV) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Human Immunodeficiency Virus (HIV) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human Immunodeficiency Virus (HIV) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Human Immunodeficiency Virus (HIV) include Merck & Co., Inc., Mylan, AbbVie, ViiV Healthcare, Genentech, Inc., Genentech, Inc., Cipla, Inc., Bristol-Myers Squibb Company and Boehringer Ingelheim GmbH, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Immunodeficiency Virus (HIV), market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Human Immunodeficiency Virus (HIV), also provides the revenue of main regions and countries. Of the upcoming market potential for Human Immunodeficiency Virus (HIV), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Immunodeficiency Virus (HIV) revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Human Immunodeficiency Virus (HIV) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Human Immunodeficiency Virus (HIV) revenue, projected growth trends, production technology, application and end-user industry.

Human Immunodeficiency Virus (HIV) Segment by Company

Merck & Co., Inc.
Mylan
AbbVie
ViiV Healthcare
Genentech, Inc.
Genentech, Inc.
Cipla, Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH
Human Immunodeficiency Virus (HIV) Segment by Type

Protease Inhibitors
NNRTIs
Coreceptor Antagonists
NRTIs
Entry and Fusion Inhibitors
Integrase Inhibitors
Human Immunodeficiency Virus (HIV) Segment by Application

Clinics
Hospitals
Labs
Human Immunodeficiency Virus (HIV) Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunodeficiency Virus (HIV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Immunodeficiency Virus (HIV) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunodeficiency Virus (HIV).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Human Immunodeficiency Virus (HIV) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Human Immunodeficiency Virus (HIV) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Immunodeficiency Virus (HIV) revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Human Immunodeficiency Virus (HIV) Market by Type
1.2.1 Global Human Immunodeficiency Virus (HIV) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Protease Inhibitors
1.2.3 NNRTIs
1.2.4 Coreceptor Antagonists
1.2.5 NRTIs
1.2.6 Entry and Fusion Inhibitors
1.2.7 Integrase Inhibitors
1.3 Human Immunodeficiency Virus (HIV) Market by Application
1.3.1 Global Human Immunodeficiency Virus (HIV) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinics
1.3.3 Hospitals
1.3.4 Labs
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Human Immunodeficiency Virus (HIV) Market Dynamics
2.1 Human Immunodeficiency Virus (HIV) Industry Trends
2.2 Human Immunodeficiency Virus (HIV) Industry Drivers
2.3 Human Immunodeficiency Virus (HIV) Industry Opportunities and Challenges
2.4 Human Immunodeficiency Virus (HIV) Industry Restraints
3 Global Growth Perspective
3.1 Global Human Immunodeficiency Virus (HIV) Market Perspective (2020-2031)
3.2 Global Human Immunodeficiency Virus (HIV) Growth Trends by Region
3.2.1 Global Human Immunodeficiency Virus (HIV) Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Human Immunodeficiency Virus (HIV) Market Size by Region (2020-2025)
3.2.3 Global Human Immunodeficiency Virus (HIV) Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Human Immunodeficiency Virus (HIV) Revenue by Players
4.1.1 Global Human Immunodeficiency Virus (HIV) Revenue by Players (2020-2025)
4.1.2 Global Human Immunodeficiency Virus (HIV) Revenue Market Share by Players (2020-2025)
4.1.3 Global Human Immunodeficiency Virus (HIV) Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Human Immunodeficiency Virus (HIV) Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Human Immunodeficiency Virus (HIV) Key Players Headquarters & Area Served
4.4 Global Human Immunodeficiency Virus (HIV) Players, Product Type & Application
4.5 Global Human Immunodeficiency Virus (HIV) Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Human Immunodeficiency Virus (HIV) Market CR5 and HHI
4.6.3 2024 Human Immunodeficiency Virus (HIV) Tier 1, Tier 2, and Tier 3
5 Human Immunodeficiency Virus (HIV) Market Size by Type
5.1 Global Human Immunodeficiency Virus (HIV) Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2031)
5.3 Global Human Immunodeficiency Virus (HIV) Revenue Market Share by Type (2020-2031)
6 Human Immunodeficiency Virus (HIV) Market Size by Application
6.1 Global Human Immunodeficiency Virus (HIV) Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2031)
6.3 Global Human Immunodeficiency Virus (HIV) Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Merck & Co., Inc.
7.1.1 Merck & Co., Inc. Comapny Information
7.1.2 Merck & Co., Inc. Business Overview
7.1.3 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.1.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
7.1.5 Merck & Co., Inc. Recent Developments
7.2 Mylan
7.2.1 Mylan Comapny Information
7.2.2 Mylan Business Overview
7.2.3 Mylan Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.2.4 Mylan Human Immunodeficiency Virus (HIV) Product Portfolio
7.2.5 Mylan Recent Developments
7.3 AbbVie
7.3.1 AbbVie Comapny Information
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.3.4 AbbVie Human Immunodeficiency Virus (HIV) Product Portfolio
7.3.5 AbbVie Recent Developments
7.4 ViiV Healthcare
7.4.1 ViiV Healthcare Comapny Information
7.4.2 ViiV Healthcare Business Overview
7.4.3 ViiV Healthcare Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.4.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Product Portfolio
7.4.5 ViiV Healthcare Recent Developments
7.5 Genentech, Inc.
7.5.1 Genentech, Inc. Comapny Information
7.5.2 Genentech, Inc. Business Overview
7.5.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.5.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
7.5.5 Genentech, Inc. Recent Developments
7.6 Genentech, Inc.
7.6.1 Genentech, Inc. Comapny Information
7.6.2 Genentech, Inc. Business Overview
7.6.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.6.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
7.6.5 Genentech, Inc. Recent Developments
7.7 Cipla, Inc.
7.7.1 Cipla, Inc. Comapny Information
7.7.2 Cipla, Inc. Business Overview
7.7.3 Cipla, Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.7.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
7.7.5 Cipla, Inc. Recent Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Comapny Information
7.8.2 Bristol-Myers Squibb Company Business Overview
7.8.3 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.8.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Product Portfolio
7.8.5 Bristol-Myers Squibb Company Recent Developments
7.9 Boehringer Ingelheim GmbH
7.9.1 Boehringer Ingelheim GmbH Comapny Information
7.9.2 Boehringer Ingelheim GmbH Business Overview
7.9.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio
7.9.5 Boehringer Ingelheim GmbH Recent Developments
7.10 Boehringer Ingelheim GmbH
7.10.1 Boehringer Ingelheim GmbH Comapny Information
7.10.2 Boehringer Ingelheim GmbH Business Overview
7.10.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2020-2025)
7.10.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio
7.10.5 Boehringer Ingelheim GmbH Recent Developments
8 North America
8.1 North America Human Immunodeficiency Virus (HIV) Revenue (2020-2031)
8.2 North America Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2031)
8.2.1 North America Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2025)
8.2.2 North America Human Immunodeficiency Virus (HIV) Revenue by Type (2026-2031)
8.3 North America Human Immunodeficiency Virus (HIV) Revenue Share by Type (2020-2031)
8.4 North America Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2031)
8.4.1 North America Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2025)
8.4.2 North America Human Immunodeficiency Virus (HIV) Revenue by Application (2026-2031)
8.5 North America Human Immunodeficiency Virus (HIV) Revenue Share by Application (2020-2031)
8.6 North America Human Immunodeficiency Virus (HIV) Revenue by Country
8.6.1 North America Human Immunodeficiency Virus (HIV) Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Human Immunodeficiency Virus (HIV) Revenue by Country (2020-2025)
8.6.3 North America Human Immunodeficiency Virus (HIV) Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Human Immunodeficiency Virus (HIV) Revenue (2020-2031)
9.2 Europe Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2031)
9.2.1 Europe Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2025)
9.2.2 Europe Human Immunodeficiency Virus (HIV) Revenue by Type (2026-2031)
9.3 Europe Human Immunodeficiency Virus (HIV) Revenue Share by Type (2020-2031)
9.4 Europe Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2031)
9.4.1 Europe Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2025)
9.4.2 Europe Human Immunodeficiency Virus (HIV) Revenue by Application (2026-2031)
9.5 Europe Human Immunodeficiency Virus (HIV) Revenue Share by Application (2020-2031)
9.6 Europe Human Immunodeficiency Virus (HIV) Revenue by Country
9.6.1 Europe Human Immunodeficiency Virus (HIV) Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Human Immunodeficiency Virus (HIV) Revenue by Country (2020-2025)
9.6.3 Europe Human Immunodeficiency Virus (HIV) Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Human Immunodeficiency Virus (HIV) Revenue (2020-2031)
10.2 China Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2031)
10.2.1 China Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2025)
10.2.2 China Human Immunodeficiency Virus (HIV) Revenue by Type (2026-2031)
10.3 China Human Immunodeficiency Virus (HIV) Revenue Share by Type (2020-2031)
10.4 China Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2031)
10.4.1 China Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2025)
10.4.2 China Human Immunodeficiency Virus (HIV) Revenue by Application (2026-2031)
10.5 China Human Immunodeficiency Virus (HIV) Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Human Immunodeficiency Virus (HIV) Revenue (2020-2031)
11.2 Asia Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2031)
11.2.1 Asia Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2025)
11.2.2 Asia Human Immunodeficiency Virus (HIV) Revenue by Type (2026-2031)
11.3 Asia Human Immunodeficiency Virus (HIV) Revenue Share by Type (2020-2031)
11.4 Asia Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2031)
11.4.1 Asia Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2025)
11.4.2 Asia Human Immunodeficiency Virus (HIV) Revenue by Application (2026-2031)
11.5 Asia Human Immunodeficiency Virus (HIV) Revenue Share by Application (2020-2031)
11.6 Asia Human Immunodeficiency Virus (HIV) Revenue by Country
11.6.1 Asia Human Immunodeficiency Virus (HIV) Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Human Immunodeficiency Virus (HIV) Revenue by Country (2020-2025)
11.6.3 Asia Human Immunodeficiency Virus (HIV) Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Human Immunodeficiency Virus (HIV) Revenue (2020-2031)
12.2 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2031)
12.2.1 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Type (2020-2025)
12.2.2 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Type (2026-2031)
12.3 SAMEA Human Immunodeficiency Virus (HIV) Revenue Share by Type (2020-2031)
12.4 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2031)
12.4.1 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Application (2020-2025)
12.4.2 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Application (2026-2031)
12.5 SAMEA Human Immunodeficiency Virus (HIV) Revenue Share by Application (2020-2031)
12.6 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Country
12.6.1 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Country (2020-2025)
12.6.3 SAMEA Human Immunodeficiency Virus (HIV) Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.